Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2008; Volume 194, Supplement 668
Belgian Society for Fundamental and Clinical Physiology and Pharmacology, Autumn Meeting 2008
11/1/2008-11/30/2008
Université Catholique de Louvain, Louvain-en-Woluwé, Belgium


PRESSOR AND RENAL EFFECTS OF ANGIOTENSIN A
Abstract number: O-02

Yang1 R., Gembardt2 F., Walther2,3 T., Lukaszuk1 A., Tourwe1 D., Vanderheyden1 P., Smolders1 I., Dupont1 A.

1Vrije Universiteit Brussel-Belgium,
2Charit Berlin Germany,
3Univ. Hull UK

Background & Objective: 

Recently a new derivative of angiotensin II (Ang II, the major bioactive peptide of the renin-angiotensin system) called angiotensin A (Ang A), was identified in human plasma, and was shown to be increased in end stage renal failure (Vera Jankowski et al. 2007). Similar to Ang II, Ang A stimulates both AT1 and AT2 receptors, although with higher affinity for AT2 receptors. The objective of the study was to investigate the blood pressure (mean blood pressure, MAP) and renal hemodynamic response (renal blood flow, RBF) to Ang A as compared with Ang II in normal adult rats and the involvement of AT1 and/or AT2 receptors in these responses. Binding properties of Ang A/II in CHO cells recombinantly expressing human AT1 receptors were also studied.

Methods and results: 

I.v. bolus injections of Ang A/II (0.01, 0.1, 1, 10 nmol/kg) dose-dependently increased MAP and decreased RBF. These effects were abolished by AT1 receptor blockade with candesartan (1 mg/kg), but were not altered by AT2 receptor blockade with PD 123315 (1 mg/kg). Intrarenal (i.r.) infusion of Ang A/II (1, 10, 100, 1000 pmol/20 ml/min) dose-dependently reduced RBF and increased MAP; these effects were blocked by candesartan (5 mg/kg, i.r.) but not affected by PD 123315 (0.5 mg/kg, i.r. bolus + 0.3 mg/h/kg, i.r. infusion). Administration of selective AT2 receptor agonists via i.v. bolus injection (CGP42112, 10 mg/kg or compound 21, 300 ng/kg) and i.r. infusion (compound 21, 1 or 10 ng/kg) did not alter MAP or RBF. Ang A was about 10 times less potent than Ang II in both i.v. bolus and i.r. infusion studies. In vitro [125I]-sar1-ile8-angiotensin binding experiments indicated that Ang A has the same nanomolar affinity for AT1 receptor compared to Ang II.

Conclusions: 

Ang A, a recently detected naturally occurring peptide, increases MAP and induces renal vasoconstriction via stimulation of AT1 receptors but is less potent than Ang II. We could not detect any AT2 receptor-mediated effect of Ang A/II on blood pressure and RBF possibly due to the low expression of these receptors in normal adult animals.

To cite this abstract, please use the following information:
Acta Physiologica 2008; Volume 194, Supplement 668 :O-02

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE